- As a nascent company with massive potential in genetic testing, Bionano Genomics, Inc. stands to gain as its OGM technology has been found complementary to other NGS technologies.
- Smart integration with previous acquisitions of Lineagen and BioDiscovery could further expand BNGO's offerings in Optical Genome Mapping (OGM).
- Nonetheless, BNGO has a history of share dilution since 2020, to fund its operations, R&D efforts, pay long-term debts, and conduct symbiotic acquisitions.
For further details see:
Bionano Stock: The Delicate Balance Between Growth And Share Dilution